Rapid Lymphatic Clearance After Subcutaneous Extravasation of 177 Lu-PSMA-I&T Radioligand Therapy.

Clin Nucl MedJun 29, 2026 (epub)
Case ReportNuclear MedicineRadiology (Diagnostic)Open access

Ruben K Fakkert, Bastiaan J van Nierop, Rob van Rooij et al.

✦ AI-curated · Sources linked

Case in brief

A patient experienced acute swelling and pain in the upper arm following subcutaneous extravasation of 177 Lu-PSMA-I&T during radioligand therapy. Imaging revealed significant radiotracer accumulation, but rapid clearance occurred within 20 hours. Conservative management was effective, with no radiation-induced tissue injury observed, paralleling outcomes seen in similar cases of 177 Lu-PSMA-617 extravasation.

Diagnostic / clinical pearl

Early imaging, such as planar scintigraphy and SPECT/CT, is crucial in assessing the extent of radiopharmaceutical extravasation and estimating absorbed doses.

Source

PubMed · PMID 42474389Free full text on PubMed Central

Published in Clin Nucl Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Nuclear Medicine

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.